Nevro Shares Rise 16% After 4Q, 2024 Revenue Guidance

Dow Jones
01-14
 

By Chris Wack

 

Nevro shares gained after the company said it expects to see fourth-quarter and full-year 2024 revenue higher than analysts' expectations.

The medical-device company's stock was up 16%, to $3.83, midday Monday.

Nevro said it expects to see quarterly earnings of $105 million to $106 million, compared with the $100.5 million analysts polled by FactSet are looking for.

For the full year, the company said it is looking for revenue of $408 million to $409 million, while analysts are forecasting revenue of $403.6 million.

Nevro said revenue is higher primarily due to the effect of greater-than-anticipated spinal cord stimulation device replacement procedures in the fourth quarter of 2024.

Cash, cash equivalents and short-term investments are expected to total $292.5 million as of Dec. 31, an increase of $15.5 million from Sept. 30.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

January 13, 2025 13:52 ET (18:52 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10